Prime Medicine Prices $125 Million Stock Offering

The Cambridge, Massachusetts biotech company priced 35,714,286 common shares at $3.50 each in an underwritten public offering.

Updated on Nov. 11, 2026 in Business

Brick and glass laboratory building on a quiet urban street under overcast winter sky, with a bare tree in the foreground.
Prime Medicine priced 35,714,286 common shares at $3.50 each, a public offering expected to raise about $125 million for the Cambridge, Massachusetts biotech company. AI Illustration. Upload story photo >

Prime Medicine, Inc. priced an underwritten public offering of 35,714,286 common shares at $3.50 per share, with all shares sold by the company. Gross proceeds are expected to be approximately $125.0 million, excluding any exercise of the underwriters' option.

Why it matters

The offering adds capital to Prime Medicine's balance sheet through a sale of new equity to public investors. Underwriters also hold a 30-day option to buy up to 5,357,142 additional shares, which could raise further proceeds.

Prime Medicine is selling 35,714,286 shares at $3.50 each for approximately $125.0 million in gross proceeds before fees. Whether the underwriters exercise their option to buy 5,357,142 more shares, which would add to total proceeds, has not been determined.

The players

Prime Medicine, Inc.

A Cambridge, Massachusetts-based biotechnology company that is the issuer of the common stock sold in this offering.

Jefferies

A global investment banking firm serving as a joint book-running manager for the Prime Medicine offering.

Goldman Sachs & Co. LLC

The investment banking arm of Goldman Sachs, serving as a joint book-running manager for the Prime Medicine offering.

TD Cowen

The investment banking division of TD Securities, serving as a joint book-running manager for the Prime Medicine offering.

The details

Jefferies, TD Cowen and Goldman Sachs & Co. LLC are joint book-running managers, with Oppenheimer & Co. and LifeSci Capital as passive book-running managers. The shares are offered under a shelf registration statement on Form S-3ASR that the SEC declared effective on March 4, 2026, and the offering is expected to close on or about November 12, 2026, subject to customary closing conditions.

Timeline

  1. November 7, 2025: Shelf registration statement filed with the SEC.

  2. March 4, 2026: SEC declared the registration statement effective.

  3. November 10, 2026: Offering pricing announced.

  4. November 12, 2026: Expected closing date of the offering.

Market Landscape

The deal uses a Form S-3ASR shelf registration, which lets eligible issuers sell securities quickly after the filing is declared effective. Companies in capital-intensive biotech often rely on this route to raise funds without a lengthy new registration each time.

Existing shareholders face dilution because 35,714,286 new shares are being added to the outstanding count. Investors buying in this offering are purchasing at $3.50 per share before the deal closes on or about November 12, 2026.

The takeaway

Equity offerings like this one trade current dilution for capital that can fund research and operations. Readers tracking the company should watch whether the underwriters exercise their option and how the proceeds are deployed.

Further reading

For more on similar equity deals, see Public Companies coverage of stock offerings and corporate capital raises.